Recently, the reporter of Science and Technology Daily learned from Harbin Medical University that under the support of several NSFC, Professor Sun Bei, the director of general surgery of the First Affiliated Hospital of Harbin Medical University, first revealed the new mechanism of long chain non coding RNAs (hereinafter referred to as lnc RNA) affecting the progress of pancreatic cancer, providing new ideas and perspectives for basic research on pancreatic cancer. At the same time, they also found that microRNA 4736, as a potential biomarker of pancreatic cancer, is expected to become an effective drug target for the treatment of pancreatic cancer. The relevant research results were recently published online in the international journal Advanced Science. According to the latest data from the National Cancer Center, pancreatic cancer ranks seventh in the incidence rate of malignant tumors in men, 11th in women, and sixth in cancer related mortality in China. According to experts, pancreatic cancer has hidden onset, atypical early symptoms, and difficult diagnosis. Most patients were in the middle and late stages of the disease when diagnosed, and lost the opportunity of surgery, resulting in poor prognosis of pancreatic cancer. Most patients had a survival period of only about one year after surgery. At this stage, with the continuous growth of the population and the aggravation of social aging, the incidence rate and mortality of pancreatic cancer are expected to continue to rise in the future. Under such a severe background, it has important theoretical significance and potential clinical application value to understand the pathogenesis of pancreatic cancer from the molecular targeting level, and then achieve accurate diagnosis and treatment of pancreatic cancer. Sun Bei's team found 489 differentially expressed lnc RNAs through transcriptomic identification of tumor tissues of patients with long-term survival (more than 5 years) and short-term survival (less than 6 months) of clinical pancreatic cancer; Compared with other differentially expressed lnc-RNA, the gene numbered lnc-FSD2-31 ∶ 1 was significantly higher in tumor tissues of long-lived patients; Further statistical analysis and molecular biology experiments showed that lnc-FSD2-31:1 could "step on the brake" for the development of pancreatic cancer. Sun Bei's team extracted tumor-related fibroblasts (CAFs) from cancer tissues with complex cell components based on the analysis of intracellular signal pathways. When co-culturing CAFs and tumor cells, it was found that the high expression of lnc-FSD2-31:1 in tumor cells can effectively inhibit the activation of CAFs. Sun Bei's team also found that inhibition of secretions carrying lnc-FSD2-31:1 could promote the activation of CAFs. These experimental results showed that the lnc-FSD2-31 ∶ 1 derived from tumor cells can further inhibit the development of tumor by inhibiting the activation of CAFs through exocrine. In addition, microribonucleic acid 4736 from exosomes inhibits autophagy of CAFs and promotes its activation by acting on autophagy gene ATG7. (Xinhua News Agency)